Please ensure Javascript is enabled for purposes of website accessibility

Why Biotech Stocks AnaptysBio, bluebird bio, and Editas Medicine Are Sinking Today

By Keith Speights - Mar 12, 2020 at 12:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Worries about a coronavirus impact don't make sense.

What happened

Shares of several biotech stocks were sinking on Thursday due to a major market sell-off related to increased worries about the impact of the coronavirus disease COVID-19. AnaptysBio (ANAB 2.60%) stock was down 8.2% as of 11:38 a.m. EDT after falling as much as 16.4% earlier in the day. Shares of bluebird bio (BLUE -2.39%) were down 11.4%. Editas Medicine (EDIT 0.73%) stock was down 11.2%.

So what

COVID-19 has been like a quicksand that's sucking down nearly every stock in sight. The main difference is that quicksand really only sucks down objects in movies and not in real life, while COVID-19 really is causing stocks to plunge.

Hand sticking out of sand

Image source: Getty Images.

But what are the real-life effects of the coronavirus pandemic on the business prospects for AnaptysBio, Bluebird, and Editas? Practically nil.

Neither AnaptysBio nor Editas have any products on the market yet. Even a pandemic can't hurt sales that don't exist. Bluebird has one product that's approved in Europe, transfusion-dependent beta-thalassemia drug Zynteglo. Physicians are just as likely to prescribe the drug for patients with the rare blood disease now as they were last week or the week before.

Now what

Expect all three biotech stocks to be highly volatile for a while even though COVID-19 really doesn't affect their businesses. Long-term investors, though, should watch key milestones for the companies instead of the wild share price swings.

AnaptysBio expects to announce results from three phase 2 clinical studies this year. Editas is moving forward with evaluating gene-editing therapy EDIT-101 in a phase 1/2 study targeting rare genetic eye disease Leber congenital amaurosis 10 (LCA 10). Bluebird plans to launch Zynteglo in other European countries in 2020 and has several regulatory filings on the way for key drugs including Lenti-D and ide-cel.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$3.27 (-2.39%) $0.08
Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
EDIT
$11.02 (0.73%) $0.08
AnaptysBio Stock Quote
AnaptysBio
ANAB
$20.88 (2.60%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.